Ascendis Pharma A/S (NASDAQ:ASND) Given New $260.00 Price Target at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND) had its target price hoisted by JPMorgan Chase & Co. from $254.00 to $260.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on ASND. Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They set an “overweight” rating and a $250.00 target price on the stock. Citigroup reissued a “buy” rating and issued a $290.00 target price (up from $243.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Wells Fargo & Company reissued an “overweight” rating and issued a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $243.36.

Ascendis Pharma A/S Trading Up 0.3%

Shares of ASND stock opened at $194.62 on Tuesday. The firm has a market capitalization of $11.91 billion, a P/E ratio of -37.72 and a beta of 0.41. The firm’s fifty day moving average price is $176.87 and its two-hundred day moving average price is $162.30. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. LPL Financial LLC increased its holdings in shares of Ascendis Pharma A/S by 60.1% in the 4th quarter. LPL Financial LLC now owns 4,199 shares of the biotechnology company’s stock valued at $578,000 after acquiring an additional 1,577 shares during the last quarter. Geode Capital Management LLC boosted its position in Ascendis Pharma A/S by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company’s stock valued at $7,858,000 after buying an additional 629 shares during the last quarter. Legal & General Group Plc lifted its holdings in Ascendis Pharma A/S by 1,577.6% during the fourth quarter. Legal & General Group Plc now owns 17,682 shares of the biotechnology company’s stock worth $2,433,000 after acquiring an additional 16,628 shares in the last quarter. Mariner LLC raised its holdings in Ascendis Pharma A/S by 31.0% during the fourth quarter. Mariner LLC now owns 2,160 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 511 shares in the last quarter. Finally, Guggenheim Capital LLC increased its position in Ascendis Pharma A/S by 256.9% during the fourth quarter. Guggenheim Capital LLC now owns 7,249 shares of the biotechnology company’s stock worth $998,000 after buying an additional 5,218 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.